Table 1.
Seven TEC trials in men with castration-resistant prostate cancer and the PSA response rates and overall survivala
| Publication | Design | Regimen | ≥50% PSA decline | Died | Median survival (months) |
| Kelly et al. [12] | Phase II | 28-day cycle: T (P) 100 mg/m2 i.v., weekly; E 10 mg/kg/day p.o., days −2 to +2 relative to TC; C AUC 6 (30 min) i.v., weekly | 36/56 (64%) | 45 (80%) | 21 |
| Urakami et al. [13] | Phase II | 28-day cycle: T (P) 100 mg/m2 i.v., weekly; E 10 mg/kg/day p.o., daily; C AUC 6 i.v., day 1 | 30/30 (100%) | 23 (77%) | 21 |
| Solit et al. [14] | Phase I/II | 28-day cycle: T (P) 100 mg/m2 i.v., weekly; E 500–1500 mg/m2 i.v., weekly; C AUC 6 (30 min) i.v., day 1 | 19/30 (63%) | 28 (93%) | 16 |
| Oh et al. CALGB [15] | Phase II | 21-day cycle: T (D) 70 mg/m2 i.v., day 2; E 840 mg/day p.o., days 1–5; C AUC 5 i.v., day 2 | 23/40 (58%) | 28 (70%) | 17 |
| Oh et al. DF/HCC [16] | Phase I | 28-day cycle: T (D) 20–43 mg/m2 i.v., days 2, 9 and 16; E 420 mg/day p.o., days 1–5, 8–12 and 15–19; C AUC 5 or 6 i.v., day 2 | 18/30 (60%) | 8 (27%) | 18 |
| Berry et al. [17] | Phase II | 28-day cycle: T (P) 80 mg/m2 i.v., days 2, 9 and 16; E 840 mg/day p.o., days 1–3, 8–10 and 15–17; C AUC 2 i.v., days 2, 9 and 16 | 50/84 (60%) | 52 (62%) | 15 |
| Kikuno et al. [18] | Phase II | 28-day cycle: T (D) 30 mg/m2 i.v., weekly; E 10 mg/kg/day p.o., daily; C AUC 6 i.v., day 1 | 38/40 (95%) | 11 (28%) | 27 |
| All | 214/310 (69%) | 195 (63%) | 18 |
a
Survival information herein is updated for several trials since the time of publication of the article.
T, taxane; E, estramustine; C, carboplatin; PSA, prostate-specific antigen; P, paclitaxel; p.o., by mouth; AUC, area under the curve (mg·min/ml); CALGB, Cancer and Leukemia Group B; D, docetaxel; DF/HCC, Dana-Farber/Harvard Cancer Center.